OPTIMIZE-1 primary analysis: Safety, efficacy and biomarker results of a phase 1b/2 study combining CD40 agonist mitazalimab with mFOLFIRINOX in previously untreated metastatic pancreatic ductal adenocarcinoma (mPDAC).

被引：0
|
作者：
Van Laethem, Jean-Luc
Borbath, Ivan
Geboes, Karen Paula
Cassier, Philippe Alexandre
Lambert, Aurelien
Mitry, Emmanuel
Prenen, Hans
Pilla, Lorenzo
Blanc, Jean-Frederic
Gallego Jimenez, Inmaculada
Cid, Roberto A. Pazo
Rodriguez Garrote, Mercedes
Feliu, Jaime
Nordbladh, Karin
Smith, Karin Enell
Gomez Jimenez, David
Ellmark, Peter
Pico de Coa, Yago
Ambarkhane, Sumeet Vijay
Macarulla, Teresa
机构：
[1] Erasme Univ Hosp, Brussels, Belgium
[2] St Luc Univ Clin, Brussels, Belgium
[3] Ghent Univ Hosp, Div Digest Oncol, Dept Gastroenterol, Ghent, Belgium
[4] Ctr Leon Berard, Lyon, France
[5] Inst Cancerol Lorraine, Vandoeuvre Les Nancy, France
[6] Inst Paoli Calmettes, Marseille, France
[7] Univ Hosp Gasthuisberg, Leuven, Belgium
[8] Univ Paris, Hop Europeen Georges Pompidou, AP HP, Dept Gastroenterol & Gastrointestinal Oncol, Paris, France
[9] Hop Haut Leveque, Pessac, France
[10] Hosp Univ Virgen Rocio, Seville, Spain
[11] Hosp Univ Miguel Servet, Zaragoza, Spain
[12] Hosp Univ Ramon y Cajal, Madrid, Spain
[13] Hosp Univ La Paz, Dept Med Oncol, Madrid, Spain
[14] Alligator Biosci AB, Lund, Sweden
[15] Vall Hebron Univ Hosp, Barcelona, Spain
[16] Vall Hebron Inst Oncol, Barcelona, Spain
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4133
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Primary results of PanCAN-SR1, a phase 1b study evaluating Gemcitabine, nab-Paclitaxel, Canakinumab, and Spartalizumab to target IL-1β and PD-1 in metastatic pancreatic cancer with correlative tissue and blood biomarker analysis
    Oberstein, Paul E.
    Rahma, Osama
    Beri, Nina
    Stoll-D'Astice, Amy
    Kawaler, Emily A.
    Dolgalev, Igor
    Werba, Gregor
    Cardo-Ruffino, Victoire
    Bollenrucher, Naima
    Costa, Andressa Dias
    Nazeer, Saloney
    Squires, Matthew
    Nowak, Jonathan
    Bar-Sagi, Dafna
    Wolpin, Brian
    Simeone, Diane M.
    Dougan, Stephanie K.
    CANCER RESEARCH, 2022, 82 (22)
  • [32] Phase 1b/2 Study of Vipor (Venetoclax, Ibrutinib, Prednisone, Obinutuzumab, and Lenalidomide) in Relapsed/Refractory and Untreated Mantle Cell Lymphoma: Safety, Efficacy, and Molecular Analysis
    Melani, Christopher
    Lakhotia, Rahul
    Pittaluga, Stefania
    Miljkovic, Milos D.
    Phelan, James D.
    Muppidi, Jagan R.
    Thomas, Craig J.
    Ceribelli, Michele
    Juanitez, Anna Marie
    Pradhan, Amynah
    Hillsman, Amy
    Steinberg, Seth M.
    Jaffe, Elaine S.
    Roschewski, Mark
    Staudt, Louis M.
    Wilson, Wyndham H.
    BLOOD, 2021, 138
  • [33] Primary analysis of a phase 1b multicenter trial to evaluate safety and efficacy of talimogene laherparepvec (T-VEC) and ipilimumab (ipi) in previously untreated, unresected stage IIIB-IV melanoma.
    Puzanov, Igor
    Milhem, Mohammed M.
    Andtbacka, Robert Hans Ingemar
    Minor, David R.
    Hamid, Omid
    Li, Ai
    Chastain, Michael
    Gorski, Kevin
    Anderson, Abraham
    Vanderwalde, Ari M.
    Chou, Jeffrey
    Kaufman, Howard
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [34] A phase 1b/2 study of the combination of the IDO pathway inhibitor indoximod and temozolomide for adult patients with temozolomide-refractory primary malignant brain tumors: Safety analysis and preliminary efficacy of the phase 1b component.
    Colman, Howard
    Mott, Frank
    Spira, Alexander I.
    Johnson, Theodore S.
    Zakharia, Yousef
    Vahanian, Nicholas N.
    Link, Charles J.
    Kennedy, Eugene Paul
    Sadek, Ramses F.
    Munn, David
    Rixe, Olivier
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [35] Updated Safety and Preliminary Efficacy Data from a Phase 1b Study Combining Venetoclax (GDC-0199, ABT-199) with Bendamustine/Rituximab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia
    Salles, Gilles A.
    Boyd, Thomas E.
    Morschhauser, Franck
    Wendtner, Clemens-Martin
    Hallek, Michael
    Eichhorst, Barbara F.
    Kozloff, Mark
    Cartron, Guillaume
    Li, Yan
    Hilger, James
    Mobasher, Mehrdad
    Stilgenbauer, Stephan
    BLOOD, 2015, 126 (23)
  • [36] Updated efficacy and safety of avelumab in metastatic urothelial carcinoma (mUC): Pooled analysis from 2 cohorts of the phase 1b Javelin solid tumor study.
    Apolo, Andrea B.
    Ellerton, John Allan
    Infante, Jeffrey R.
    Agrawal, Manish
    Gordon, Michael S.
    Aljumaily, Raid
    Britten, Carolyn D.
    Dirix, Luc Yves
    Lee, Keun-Wook
    Taylor, Matthew H.
    Schoffski, Patrick
    Wang, Ding
    Ravaud, Alain
    Gelb, Arnold
    Xiong, Junyuan
    Rosen, Galit
    Patel, Manish R.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [37] Safety and efficacy of IBI389, an anti-CLDN18.2/CD3 bispecific antibody, in patients with advanced pancreatic ductal adenocarcinoma: Preliminary results from a phase 1 study.
    Hao, Jihui
    Zheng, Li
    Dai Ruihong
    Ying Jieer
    Xu, Qi
    Wang, Li-Wei
    Jin, Yongdong
    Zhao, Ying
    Pan, Yueyin
    Liu, Lulu
    Zhang, Jun
    Sun, Yuping
    Niu, Zuoxing
    Yao, Jun
    Hua, Dong
    Zhang, Mingjun
    Dai Guanghai
    Zhang, Yulong
    Zhou, Hui
    Bi, Feng
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [38] A phase 1b, open-label, two-part safety, tolerability, and efficacy study of a soluble beta-glucan (odetiglucan) in combination with a CD40 agonistic monoclonal antibody (CDX1140) in patients with metastatic pancreatic adenocarcinoma whose disease did not progress during first-line (1L) chemotherapy.
    O'Hara, Mark H.
    Wattenberg, Max Miller
    Garrido-Laguna, Ignacio
    O'Reilly, Eileen Mary
    Yellin, Michael Jay
    Keler, Tibor
    Gargano, Michele Anne
    Niles, Nick
    Drees, Jeremy
    Bose, Nandita
    Iglesias, Jose Luis
    Beatty, Gregory Lawrence
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [39] Pivot-02: Preliminary safety, efficacy and biomarker results from the Phase 1/2 study of CD-122-biased agonist NKTR-214 plus nivolumab in patients with locally advanced/metastatic solid tumors
    Diab, Adi
    Tannir, Nizar
    Cho, Daniel
    Papadimitrakopoulou, Vali
    Bernatchez, Chantale
    Haymaker, Cara
    Bentebibel, Salah Eddine
    Curti, Brendan
    Wong, Michael
    Tykodi, Scott
    Puzanoff, Igor
    Smalberg, Ira
    Gergel, Ivan
    Tagliaferri, Mary
    Zalevsky, Jonathan
    Hoch, Ute
    Aung, Sandra
    Imperiale, Michael
    Clemens, Wendy
    Kluger, Harriet
    Hurwitz, Michael
    Hwu, Patrick
    Sznol, Mario
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2017, 5
  • [40] Safety and Efficacy of a Combination of Venetoclax (GDC-0199/ABT-199) and Obinutuzumab in Patients with Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia - Results from a Phase 1b Study (GP28331)
    Flinn, Ian W.
    Brunvand, Mark
    Choi, Michael Y.
    Dyer, Martin J. S.
    Gribben, John
    Hillmen, Peter
    Jones, Jeffrey
    Li, Yan
    Mobasher, Mehrdad
    Vosganian, Gregory
    Kipps, Thomas J.
    BLOOD, 2015, 126 (23)
12345